Evidence map›Paper›PMID 38394984›Full record

ArticleESMO open2024

Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM).

R Berardi, F Rossi, R Papa, M Appetecchia, G Baggio, M Bianchini, T Mazzei, A Maria Moretti, E Ortona, F Pietrantonio and 3 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

R BerardiMedical Oncology, Polytechnic University of Marche Region, Ancona; Medical Oncology, AOU Marche, Ancona, Italy - National Councilor AIOM (Italian Association of Medical Oncology); Treasurer AIOM (Italian Association of Medical Oncology). Electronic address: r.berardi@univpm.it.
F RossiMedical Oncology, Polytechnic University of Marche Region, Ancona.
R PapaQuality, Risk Management and Health Technology Innovation Unit, Department of Staff, AOU Marche, Ancona.
M AppetecchiaOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome.
G BaggioPresident of the Italian Research Center for Gender Health and Medicine, Chair of Gender Medicine 2012-2017, University of Padua, Padua.
M BianchiniOncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome.
T MazzeiDepartment of Pharmacology, University of Florence, Florence.
A Maria MorettiNational President of the Scientific Society GISeG (Italian Group Health and Gender); President of the International Society IGM (International Gender Medicine).
E OrtonaHead - Center for Gender-specific Medicine, Italian National Institute of Health, Rome.
F PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
V TarantinoMedical Oncology, Polytechnic University of Marche Region, Ancona.
T VavalàSC of Oncology 1U, Department of Oncology, AOU Città della Salute e della Scienza, Torino; AIOM (Italian Association of Medical Oncology); GISeG (Italian Group Health and Gender).
S CinieriMedical Oncology and Breast Unit, Perrino Hospital, Brindisi; President of AIOM Foundation (Italian Association of Medical Oncology), Italy.
Marche Polytechnic University · ITCancer Institute (WIA) · INGroup Health Cooperative · USFondazione IRCCS Istituto Nazionale dei Tumori · ITNational Institute of Health · AMOspedale A. Perrino · ITUniversity of Florence · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing the development of gender medicine in the past 20 years, more recently in the field of oncology an increasing amount of evidence suggests gender differences in the epidemiology of cancers, as well as in the response and toxicity associated with therapies. In a gender approach, critical issues related to sexual and gender minority (SGM) populations must also be considered. MATERIALS AND

methodsA working group of opinion leaders approved by the Italian Association of Medical Oncology (AIOM) has been set up with the aim of drafting a shared document on gender oncology. Through the 'consensus conference' method of the RAND/University of California Los Angeles (UCLA) variant, the members of the group evaluated statements partly from the scientific literature and partly produced by the experts themselves [good practice points (GPPs)], on the following topics: (i) Healthcare organisation, (ii) Therapy, (iii) Host factors, (iv) Cancer biology, and (v) Communication and social interventions. Finally, in support of each specific topic, they considered it appropriate to present some successful case studies.

resultsA total of 42 articles met the inclusion criteria, from which 50 recommendations were extracted. Panel participants were given the opportunity to propose additional evidence from studies not included in the research results, from which 32 statements were extracted, and to make recommendations not derived from literature such as GPPs, four of which have been developed. After an evaluation of relevance by the panel, it was found that 81 recommendations scored >7, while 3 scored between 4 and 6.9, and 2 scored below 4.

conclusionsThis consensus and the document compiled thereafter represent an attempt to evaluate the available scientific evidence on the theme of gender oncology and to suggest standard criteria both for scientific research and for the care of patients in clinical practice that should take gender into account.

Indexed as

Medical OncologyNeoplasmsHumansItalyanticancer therapiescancerepidemiologygender oncologyoutcome and toxicity

Identifiers

PMID38394984
PMCPMC10937209
OpenAlexW4392125589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.